
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Shandong Weigao Group Medical Polymer Company Limited, you should at once hand this circular and the enclosed proxy form to the purchaser or transferee or to the bank or licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

(1) GENERAL MANDATE TO ISSUE H SHARES AND DOMESTIC SHARES
(2) GENERAL MANDATE TO REPURCHASE H SHARES
(3) PROPOSED RE-ELECTION OF DIRECTORS AND SUPERVISOR
(4) PROPOSED FINAL DIVIDEND
AND
(5) NOTICE OF ANNUAL GENERAL MEETING

The notice convening the Annual General Meeting of the Company to be held at 2/F, 1 Weigao Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the People's Republic of China (the "PRC") at 9:00 a.m. on Tuesday, 27 May 2025 are set out on pages 25 to 30 of this circular.

Whether or not you are able to attend the meeting, you are strongly urged to complete and sign the enclosed forms of proxy in accordance with the instructions printed thereon and please return it to the Company's H Share registrar, Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible but in any event not later than 24 hours before the time appointed for the holding of the relevant meeting or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the meeting or any adjourned meeting should you so wish.

30 April 2025

* For identification purpose only

CONTENTS

	Page
DEFINITIONS	1
LETTER FROM THE BOARD	
Introduction	4
General Mandates to Issue H Shares and Domestic Shares	5
General Mandate to Repurchase H Shares.	6
Proposed Re-election for Directors and Supervisor.	7
Proposed Final Dividend Payment.	8
Annual General Meeting and Closure of Registered Members	13
Voting By Poll.	15
Recommendation.	15
Additional Information	15
APPENDIX I – EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE.	16
APPENDIX II – PARTICULAR OF THE DIRECTORS AND SUPERVISORS PROPOSED FOR ELECTION	21
NOTICE OF ANNUAL GENERAL MEETING	25

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

“Annual General Meeting” or “AGM”	the annual general meeting of the Company to be held on Tuesday, 27 May 2025 at 9:00 a.m. at 2/F, 1 Weigao Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the PRC, notice of which is set out on pages 25 to 30 of this circular
“Articles of Association”	the articles of association of the Company (as amended from time to time)
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors
“Business Day(s)”	any day (excluding a Saturday, Sunday and public holiday) on which licensed banks are generally open for business in Hong Kong
“Company”	Shandong Weigao Group Medical Polymer Company Limited* (山東威高集團醫用高分子製品股份有限公司), a joint stock limited company incorporated in the PRC with limited liability
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Directors”	the directors of the Company
“Domestic Shares”	non-listed domestic shares of RMB0.10 each in the share capital of the Company
“Group”	the Company and its subsidiaries
“H Shares”	the overseas-listed foreign invested shares in the share capital of the Company, with a nominal value of RMB0.10 each, which are held and traded in Hong Kong dollars
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China

DEFINITIONS

“Issue Mandate”	a general and unconditional mandate proposed to be granted to the Directors to exercise all powers of the Company to issue, allot or otherwise deal with additional shares in the capital of the Company up to a maximum of 20% of the aggregate nominal amount of the H Shares and Domestic Shares respectively in issue (excluding any treasury shares) as at the date of passing the relevant resolutions at the Annual General Meeting
“Latest Practicable Date”	24 April 2025, being the latest practicable date for ascertaining certain information contained in this circular prior to its publication
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China, excluding, for the purpose of this circular only, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“PRC Company Law”	The Company Law of the PRC
“Repurchase Mandate”	a general and unconditional mandate proposed to be granted to the Directors to exercise all powers of the Company to repurchase H Shares with an aggregate nominal value not exceeding 10% of the aggregate nominal value of H Shares in issue (excluding any treasury shares) as at the date of passing the relevant resolution at the Annual General Meeting
“RMB”	Renminbi, the lawful currency of the PRC
“SAFE”	the State Administration of Foreign Exchange of the PRC
“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	issued shares of the Company, comprise both H Shares and Domestic Shares

DEFINITIONS

“Share Award Scheme”	The share award scheme of the Company adopted on 17 November 2014
“Shareholder(s)”	the holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisor(s)”	the supervisor(s) of the Company
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers
“treasury shares”	has the meaning ascribed to it under the Listing Rules
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“%”	per cent.

LETTER FROM THE BOARD

WEGO威高

山東威高集團醫用高分子製品股份有限公司 **Shandong Weigao Group Medical Polymer Company Limited ***

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

Executive Directors:

Mr. Long Jing (*Chairman*)
Mr. Cong Rinan (*Chief Executive Officer*)
Mr. Lu Junqiang
Mr. Wang Daoming

Non-executive Directors:

Mr. Tang Zhengpeng (*Vice Chairman*)
Mr. Chen Lin
Mrs. Yan Xia

Independent non-executive Directors:

Mr. Li Guohui
Mrs. Meng Hong
Mr. Li Qiang
Mr. Sun Heng

Principal place of business in the PRC:

1 Weigao Road
Torch Hi-tech Science Park
Weihai
Shandong Province
China

*Principal place of business
in Hong Kong:*

29/F., Two Chinachem Central
26 Des Voeux Road Central
Hong Kong

30 April 2025

To Shareholders

Dear Sir or Madam,

- (1) GENERAL MANDATE TO ISSUE H SHARES AND DOMESTIC SHARES**
(2) GENERAL MANDATE TO REPURCHASE H SHARES
(3) PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND
SUPERVISOR
(4) PROPOSED FINAL DIVIDEND
AND
(5) NOTICE OF ANNUAL GENERAL MEETING

INTRODUCTION

The purpose of this circular is to provide you with information regarding the resolutions to be proposed at the Annual General Meeting relating to, among other matters, (i) the proposed grant of the Issue Mandate; (ii) the proposed grant of Repurchase Mandate; (iii) the proposed re-election of the Directors and Supervisor; and (iv) the proposed final dividend payment.

* For identification purpose only

LETTER FROM THE BOARD

GENERAL MANDATE TO ISSUE H SHARES AND DOMESTIC SHARES

In order to provide the Board with flexibility and discretion to issue H Shares and Domestic Shares in the event that it becomes desirable to issue any such shares, a special resolution will be proposed at the Annual General Meeting to grant to the Board the Issue Mandate.

Pursuant to the Issue Mandate, a general and unconditional mandate is to be granted to the Board to exercise the power of the Company to separately or concurrently to issue, allot and/or deal with additional H Shares and/or Domestic Shares (including but not limited to ordinary shares, preference shares, securities convertible into shares, options, warrants or similar rights to subscribe for any shares or such convertible securities, and to resell any treasury shares repurchased) up to the limit of 10% of each of its existing H Shares and Domestic Shares of the Company (excluding any treasury shares) as at the date of passing the relevant resolution at the Annual General Meeting. The discount (if any) of the issue price of the H Shares and/or Domestic Shares to be allotted, issued and dealt with as determined by the Board or the chairman of the Board and its authorized persons in accordance with the Issue Mandate shall not exceed 10% of the benchmark price of the securities (rather than the 20% as prescribed under the Listing Rules).

The Issue Mandate, if approved, shall be effective from the date of passing the relevant resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of the relevant resolution;
- (ii) the expiration of the 12-month period following the passing of the relevant resolution;
or
- (iii) the date on which the authority granted to the Board as set out in the relevant resolution is revoked or varied by a special resolution of the Shareholders in a general meeting.

No class meeting shall be required to be convened for approval by the Company when the Board exercises the general mandate to issue, allot and deal with H Shares and/or Domestic Shares (including but not limited to ordinary shares, preference shares, securities convertible into shares, options, warrants or similar rights to subscribe for any shares or such convertible securities). The obtaining of the Issue Mandate is in accordance with the Listing Rules, the Articles of Association and the applicable laws, rules and regulations of government and regulatory authorities of the PRC.

The Board will only exercise its power under the Issue Mandate in accordance with the relevant requirements of the PRC Company Law, the Listing Rules and other applicable laws, rules and regulations of other government regulatory bodies.

LETTER FROM THE BOARD

As at the Latest Practicable Date, the Company has 4,517,512,324 H Shares (excluding 4,820,000 treasury shares) and 48,300,000 Domestic Shares in issue. Subject to the passing of the resolution in relation to the Issue Mandate, the Company may allot, issue and deal with up to 451,751,232 H Shares and/or 4,830,000 Domestic Shares (on the basis that the Company will not issue or repurchase any H Shares and/or Domestic Shares before the Annual General Meeting).

GENERAL MANDATE TO REPURCHASE H SHARES

The PRC Company Law (to which the Company is subject) provides that a joint stock limited company incorporated in the PRC shall not repurchase its shares except under any of the following circumstances: (a) in order to reduce the registered capital of the company; (b) merger with another company holding shares in the Company; (c) the shares are used for employee stock ownership plan or equity incentives; (d) a shareholder requests the Company to purchase the shares held by him/her since he/she objects to a resolution of the shareholders' meeting on the combination or division of the Company; (e) the shares are used for converting convertible corporate bonds issued by the listed company; or (f) when it is necessary for the listed company to preserve its value and shareholders' rights and interests.

The Listing Rules permits shareholders of a PRC joint stock limited company to grant a general mandate to its directors to repurchase H shares of such company that are listed on the Stock Exchange. According to the Articles of Association, such mandate is required to be given by way of a special resolution passed by the Shareholders at general meeting.

As H Shares are traded on the Stock Exchange in Hong Kong dollars and the price payable by the Company upon any repurchase of H Shares shall, therefore, be paid in Hong Kong dollars, the payment of the repurchase price is subject to the approval of SAFE or entities authorised by it.

Based on the actual number of H Shares repurchased, cancelled and reduced in the Company's registered capital, the Board will be authorised to notify the creditors of the Company, issue announcements and convene meetings of bondholders pursuant to the requirements under relevant laws and regulations and the Articles of Association, and register the changes and/or filing and related matters.

In order to provide more flexibility to the Directors to repurchase H Shares, a special resolution will be proposed at the Annual General Meeting to grant to the Board the Repurchase Mandate.

Pursuant to the Repurchase Mandate, the H Shares which may be repurchased shall not exceed 10% of the total number of H Shares in issue (excluding any treasury shares) as at the date of passing of the relevant resolution.

LETTER FROM THE BOARD

The Repurchase Mandate will be conditional upon the special resolution for approving the granting of the Repurchase Mandate being passed at the Annual General Meeting. The Repurchase Mandate, if approved, shall be effective from the date of passing the relevant resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of the relevant resolution at the Annual General Meeting;
- (ii) the expiration of the 12-month period following the passing of the relevant resolution at the Annual General Meeting; or
- (iii) the date on which the authority granted to the Board as set out in the relevant resolution is revoked or varied by a special resolution of the Shareholders in a general meeting.

The obtaining of the Repurchase Mandate is in accordance with the Listing Rules, the Articles of Association and the applicable laws, rules and regulations of government and regulatory authorities of the PRC.

An explanatory statement containing information regarding the Repurchase Mandate is set out in Appendix I to this circular.

PROPOSED RE-ELECTION FOR DIRECTORS AND SUPERVISOR

Re-election of Directors

The term of office of Mr. Long Jing, Mr. Lu Junqiang and Mr. Li Guohui are due to expire at the Annual General Meeting. Mr. Long Jing, Mr. Lu Junqiang and Mr. Li Guohui, being eligible, shall offer themselves for re-election at the Annual General Meeting.

Re-election of Supervisor

Mr. Song Dapeng has been appointed as the shareholders representative supervisor in May 2022. The term of office of Mr. Song Dapeng is due to expire at the Annual General Meeting. Mr. Song Dapeng, being eligible, shall offer himself for re-election at the Annual General Meeting.

Particulars of the Directors and Supervisor proposed for re-election at the Annual General Meeting are set out in Appendix II to this circular.

LETTER FROM THE BOARD

PROPOSED FINAL DIVIDEND PAYMENT

According to the Company's dividend policy and the relevant provisions of the Articles of Association, the Board proposed the profit distribution plan of the Company for the year ended 31 December 2024 and proposed the payment of a final cash dividend of RMB0.1235 per Share (before tax) for the year ended 31 December 2024 (2023: RMB0.0943). The profit distribution plan had been considered and approved by the Board on 26 March 2025, and is hereby submitted to the Shareholders for consideration and approval at the Annual General Meeting.

If the abovementioned profit distribution plan is approved by the Shareholders at the Annual General Meeting, the proposed cash dividend shall be paid on or before Friday, 11 July 2025 to the Shareholders whose names appear on the register of the members of the Company on Tuesday, 10 June 2025. Dividends shall be paid in RMB for Domestic Shares whereas dividends shall be denominated in RMB and paid in HKD for H Shares (the exchange rate for RMB to HKD shall be calculated based on the average selling price for conversion for RMB to HKD released by the People's Bank of China for a calendar week before the date of Annual General Meeting). Specific arrangements for the payment of the final dividends for the year ended 31 December 2024 (including the arrangements of withholding and payment of income tax) are as follows:

Information to the Shareholders

(1) Domestic Shareholders

For enterprise Domestic Shareholders:

The Company will not withhold or pay any income tax for domestic enterprise Shareholders in accordance with the applicable provisions of the Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法》) and its implementation regulations. They are required to pay their own income tax. The final dividend for Domestic Shareholders without affirmed ownership will be kept temporarily by the Company and will be distributed once their ownership has been confirmed.

LETTER FROM THE BOARD

For individual Domestic Shareholders:

The Company will pay the final dividend for the year ended 31 December 2024 while withhold and pay the individual income tax at the rate of 20% for Shareholders who are natural persons and whose names appear on the register of members for the Domestic Shares on Tuesday, 10 June 2025 according to the applicable provisions of the Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法》).

(2) H Shareholders

The Company will not process any registration of transfers of H Shares from Wednesday, 4 June 2025 to Tuesday, 10 June 2025 (both days inclusive). In order to be entitled to the final dividend for the year ended 31 December 2024, H Shareholders shall deliver the share certificates accompanied by the transfer documents to the Company's H Share registrar Tricor Investor Services Limited not later than 4:30 p.m. on Tuesday, 3 June 2025.

For Enterprise H Shareholders:

According to the Enterprise Income Tax Law of the People's Republic of China (中華人民共和國企業所得稅法) which came into effect on January 1, 2008 and its implementation regulations and other relevant rules, the Company is required to withhold enterprise income tax at the rate of 10% before distributing the final dividend to nonresident enterprise Shareholders as appearing on the register of members for H shares. Any H shares registered in the name of non-individual registered Shareholders, including HKSCC Nominees Limited, other nominees, trustees or other groups or organizations will be treated as being held by non-resident enterprise Shareholders, whose dividends entitled shall be subject to the withholding of the enterprise income tax.

LETTER FROM THE BOARD

For Individual H Shareholders:

According to regulations of the State Administration of Taxation (Guo Shui Han [2011] No. 348) (《國家稅務總局國稅函([2011]348號)》) and the Administrative Measures for Non-Resident Taxpayers to Enjoy Treaty Benefits (Announcement No. 35 [2019] of the State Administration of Taxation) (“Tax Convention Announcement”) (《非居民納稅人享受協定待遇管理辦法》) (國家稅務總局公告[2019]35號), the Company is required to withhold and pay individual income tax when distributing dividends to individual H Shareholders. However, the individual H Shareholders may be entitled to relevant tax preferential treatments pursuant to the tax treaties between the PRC and the countries (regions) in which the individual H Shareholders are domiciled and the tax arrangements between Mainland China and Hong Kong or Macau. In this regard, the Company will implement the following arrangements in relation to the withholding and payment of individual income tax for the individual H Shareholders:

- for individual H Shareholders who are Hong Kong or Macau residents or whose country (region) of domicile is a country (region) which has entered into a tax treaty with the PRC stipulating a tax rate of 10%, the Company will withhold and pay individual income tax at the rate of 10% on behalf of the individual H Shareholders in the distribution of the final dividend.
- for individual H Shareholders whose country (region) of domicile is a country (region) which has entered into a tax treaty with the PRC stipulating a tax rate of less than 10%, the Company will temporarily withhold and pay individual income tax at the rate of 10% on behalf of the individual H Shareholders in the distribution of final dividend. If relevant individual H Shareholders would like to apply for a refund of the excess amount of tax withheld and paid, they should submit the required written power of attorney and all submission materials to the Company and collect and retain relevant information themselves for future inspection. The Company will handle, on their behalf, the applications for tax preferential treatments under relevant tax treaties according to the Tax Convention Announcement. The Company will then submit the above documents to competent tax authorities and, after their review and approval, the Company will assist in refunding the excess amount of tax withheld and paid.

LETTER FROM THE BOARD

- for individual H Shareholders whose country (region) of domicile is a country (region) which has entered into a tax treaty with the PRC stipulating a tax rate of more than 10% but less than 20%, the Company will withhold and pay individual income tax at the effective tax rate stipulated in the relevant tax treaty in the distribution of final dividend.
- for individual H Shareholders whose country (region) of domicile is a country (region) which has entered into a tax treaty with the PRC stipulating a tax rate of 20%, or a country (region) which has not entered into any tax treaties with the PRC, or under any other circumstances, the Company will withhold and pay individual income tax at the rate of 20% on behalf of the individual H Shareholders in the distribution of final dividend.

(3) Hong Kong Stock Connect Shareholders

Pursuant to the relevant requirements under the Notice on the Tax Policies

Related to the Pilot Program of the Shanghai-Hong Kong Stock Connect (Cai Shui [2014] No. 81) 《(關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知(財稅[2014]81號))》, which came into effect on 17 November 2014, for dividends received by domestic individual investors from investing in H shares listed on the Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect, the company of such H shares shall withhold and pay individual income tax at the rate of 20% on their behalf. For dividends received by domestic securities investment funds from investing in H shares listed on the Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect, the tax payable shall be the same as that for individual investors. The company of such H shares will not withhold and pay the income tax on dividends for domestic enterprise investors. Those domestic enterprise investors shall file and pay the relevant tax themselves while for the dividend and bonus income received by domestic resident enterprises from holding H shares for 12 consecutive months, enterprise income tax shall be exempted according to law.

LETTER FROM THE BOARD

Pursuant to the relevant requirements under Notice on Relevant Taxation Policies

Concerning the Pilot Interconnected Mechanism for Trading on the Shenzhen Stock Market and the Hong Kong Stock Market (Cai Shui [2016] No. 127) 《關於深港股票市場交易互聯互通機制試點有關稅收政策的通知(財稅[2016]127號)》 promulgated on December 5, 2016, for dividends received by domestic individual investors from investing in H shares listed on the Hong Kong Stock Exchange through Shenzhen Hong Kong Stock Connect, the company of such H shares shall withhold and pay individual income tax at the rate of 20% on their behalf. For dividends received by domestic securities investment funds from investing in H shares listed on the Hong Kong Stock Exchange through Shenzhen Hong Kong Stock Connect, the tax payable shall be the same as that for individual investors; and for dividends received by domestic enterprise investors from investing in H shares listed on the Hong Kong Stock Exchange through Shenzhen Hong Kong Stock Connect, the company of such H shares shall not withhold and pay the income tax on their behalf and the domestic enterprise investors shall file tax returns themselves while for the dividend and bonus income obtained by domestic resident enterprises from holding of H share for 12 consecutive months, enterprise income tax shall be exempted accordingly to law.

Pursuant to the Notice on Relevant Taxation Policies Concerning Interim Income

Tax Exemption for Profit Distribution Received and Utilized by Foreign Investors for Direct Investment (Cai Shui [2017] No. 88) 《關於境外投資者以分配利潤直接投資暫不徵收預提所得稅政策問題的通知(財稅[2017]88號)》, which came into effect on 1 January 2017, for profits distributed to foreign investors by domestic resident enterprises, where such profits are utilized to directly invest in qualified encouraging investment projects, deferred tax collection policies shall be applicable and income tax temporarily exempted thereby. Qualified non-resident enterprises Shareholders proposed to apply for the application of this tax policy shall, in accordance with the announcement of [2018] No. 3 of the State Administration of Taxation 《國家稅務總局[2018]3號公告》, deliver relevant information and documents to the Company in advance for early review by and filing with the competent taxation authorities. The Company will not withhold any enterprise income tax upon the completion of such review and filing. The Company will determine the residency status of the individual H Shareholders based on the registered addresses as recorded in the register of members of H Shares on Tuesday, 10 June 2025 (the “**Registered Address**”). If the residency status of any individual H Shareholder is not in consistency with that indicated by the Registered Address, such individual H Shareholder shall notify the Company’s H Share registrar Tricor Investor Services Limited not later than 4:30 p.m. on Tuesday, 3 June 2025 and provide relevant supporting documents. Any individual H Shareholder who fails to provide relevant supporting documents within the time period stated above may either personally or through appointing an agent handle the relevant procedures in accordance with the requirements under the tax treaty notice.

LETTER FROM THE BOARD

The Company assumes no responsibility and disclaims all liabilities whatsoever in relation to the tax status or tax treatment of the individual H Shareholders and for any claims arising from any delay in or inaccurate determination of the tax status or tax treatment of the individual H Shareholders or any disputes over the withholding mechanism or arrangements.

ANNUAL GENERAL MEETING AND CLOSURE OF REGISTERED MEMBER

The Annual General Meeting will be held at 9:00 a.m. on Tuesday, 27 May 2025 at 2/F., 1 Weigao Road, Torch Hi-tech Science Park, Weihai, Shandong, the PRC for the purpose of, inter alia, considering and approving, by the Shareholders, by way of resolutions: (i) the proposed grant of Issue Mandate; (ii) the proposed grant of Repurchase Mandate; (iii) the proposed re-election of Directors and Supervisor; and (iv) the proposed final dividend payment. The notice convening the Annual General Meeting at which the resolutions mentioned above will be proposed are set out on pages 25 to 30 to this circular.

As at the Latest Practicable Date, the grantees who held a total of 48,300,000 Domestic Shares and 14,456,000 H Shares under the Share Award Scheme will not exercise the voting rights attached to any Shares held by them.

The proxy form for use at the Annual General Meeting is enclosed and is also published on the websites of the Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (<http://www.weigaogroup.com>). Whether or not you are able to attend the Annual General Meeting, you are strongly urged to complete and sign the enclosed form of proxy in accordance with the instructions printed thereon. For holders of H Shares, please return it to the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible but in any event not later than 24 hours before the time appointed for the holding of the relevant meeting or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the meeting or any adjourned meeting should you so wish.

The register of members of the Company will be closed from Wednesday, 21 May 2025 to Tuesday, 27 May 2025 (both days inclusive), for the purpose of determining shareholders' entitlement to attend the Annual General Meeting, during which period no transfer of shares of the Company will be registered. In order to qualify for attending the Annual General Meeting, shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration no later than 4:30 p.m. on Tuesday, 20 May 2025.

LETTER FROM THE BOARD

In order to qualify for attending the Annual General Meeting:–

Latest time to lodge in transfer instrument accompanied
by the share certificates for H Shares 4:30 p.m. on Tuesday, 20 May 2025

Closure of register of members of the Company
for attending and voting in the
Annual General Meeting Wednesday, 21 May 2025 to
Tuesday, 27 May 2025

Date of Annual General Meeting. Tuesday, 27 May 2025

The register of members of the Company will be closed from Wednesday, 4 June 2025 to Tuesday, 10 June 2025 (both days inclusive) for the purpose of determining shareholders' entitlement to final dividend for the year ended 31 December 2024, during which period no transfer of shares of the Company will be registered. In order to qualify for entitlement of final dividend, shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration no later than 4:30 p.m. on Tuesday, 3 June 2025.

In order to qualify to entitle the final dividend for the year ended 31 December 2024:–

Latest time to lodge in transfer instrument accompanied
by the share certificates for H Shares
and Domestic Shares. 4:30 p.m. on Tuesday, 3 June 2025

Closure of register of members of the Company
for entitlement of the final dividend for
the year ended 31 December 2024 Wednesday, 4 June 2025 to
Tuesday, 10 June 2025

Record date for the entitlement of the final dividend Tuesday, 10 June 2025

Expected dispatch date of the final dividend. Friday, 11 July 2025

The final dividend will be despatched at the risk of those entitled thereto to their respective registered addresses on or before Friday, 11 July 2025.

LETTER FROM THE BOARD

VOTING BY POLL

In accordance with Rule 13.39(4) of the Listing Rules, all votes of the Shareholders to be taken at the Annual General Meeting will be taken by poll. An announcement of the results of the poll will be published after the Annual General Meeting in accordance with the requirements of the Listing Rules.

RECOMMENDATION

The Directors consider that the resolutions to be put before the Annual General Meeting are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that the Shareholders to vote in favour of all the aforesaid resolutions to be proposed at the Annual General Meeting.

ADDITIONAL INFORMATION

Your attention is drawn to the additional information set out in the Appendices to this circular.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

This appendix serves as an explanatory statement, as required by the Listing Rules, to provide you with requisite information reasonably necessary to enable you to make an informed decision on whether to vote for or against the special resolutions to be proposed at the Annual General Meeting for the granting of the Repurchase Mandate to the Board.

1. LISTING RULES

The Listing Rules permit companies with a primary listing on the Stock Exchange to repurchase their securities on the Stock Exchange subject to certain restrictions. Repurchases must be funded out of funds legally available for the purpose and in accordance with the company's constitutional documents and the applicable laws of the jurisdiction in which the company is incorporated or otherwise established. Any premium payable on a repurchase over the par value of the shares may be effected out of book balance of distributable profits of the Company or proceeds of a new issue of shares made for such purpose.

2. REASONS FOR THE REPURCHASES OF H SHARES

The Directors believe that it is in the best interests of the Company and the Shareholders as a whole to seek a general authority from the Shareholders to enable the Company to repurchase H Shares in the market. Such repurchase may, depending on the market conditions and funding arrangement at the time, lead to an enhancement of the net assets value and/or earnings per Share of the Company and will only be made when the Directors believe that such a repurchase will benefit the Company and the Shareholders.

3. REGISTERED CAPITAL

As at the Latest Practicable Date, the number of total issued shares of the Company was 4,565,812,324, comprising 4,517,512,324 H Shares (excluding 4,820,000 treasury shares) and 48,300,000 Domestic Shares.

4. EXERCISE OF THE REPURCHASE MANDATE

Subject to the passing of the special resolution approving the grant of the Repurchase Mandate at the Annual General Meeting, the Directors will be granted the Repurchase Mandate until the earliest of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of the relevant resolution at the Annual General Meeting;
- (ii) the expiration of the 12-month period following the passing of the relevant resolution at the Annual General Meeting; or
- (iii) the date on which the authority granted to the Board as set out in the relevant resolution is revoked or varied by a special resolution of the Shareholders in a general meeting.

(hereinafter referred to as the “**Relevant Period**”).

The exercise of the Repurchase Mandate is subject to relevant approval of and/or filings with the relevant regulatory authorities as required by the laws, rules and regulations of the PRC being obtained and/or carried out and the Company not being required by any of its creditors to repay or to provide guarantee in respect of any amount due to any of them (or if the Company is so required by any of its creditors, the Company having, in its absolute discretion, repaid or provided guarantee in respect of such amount using internal resource) pursuant to the notification procedure set out in the relevant article of the Articles of Association. The notification to the creditors will not be issued until the Annual General Meeting to be convened have approved the Repurchase Mandate by way of special resolution.

The exercise in full of the Repurchase Mandate (on the basis of 4,517,512,324 H Shares in issue (excluding 4,820,000 treasury shares) as at the Latest Practicable Date and no H Shares will be allotted and issued or repurchased by the Company on or prior to the date of the Annual General Meeting) would result in a maximum of 451,751,232 H Shares being repurchased by the Company during the Relevant Period, being the maximum of 10% of the total H Shares in issue (excluding any treasury shares) as at the date of passing the relevant resolution at the Annual General Meeting.

5. FUNDING OF REPURCHASE

In repurchasing its H Shares, the Company intends to apply funds from the Company’s internal resources legally available for such purpose in accordance with the Articles of Association and the applicable laws, rules and regulations of the PRC.

The Company is empowered by the Articles of Association to purchase its H Shares. Any repurchases by the Company may only be made out of either the funds of the Company that would otherwise be available for dividend or distribution or out of the proceeds of a new issue of shares made for such purpose. The Company may not purchase securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

Based on the financial position disclosed in the latest published audited accounts of the Company for the year ended 31 December 2024, the Directors consider that there will not be any material adverse impact on the working capital or gearing position of the Company in the event that the Repurchase Mandate is to be exercised in full at any time during the proposed repurchase period. The number of H Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regard to the circumstances then prevailing and in the best interests of the Company.

6. H SHARES PRICES

The highest and lowest prices at which the H Shares have been traded on the Stock Exchange during each of the previous 12 months preceding the Latest Practicable Date were as follows:

	Trading price per Share	
	Highest (HK\$)	Lowest (HK\$)
2024		
April	5.34	4.51
May	5.43	4.56
June	4.57	3.72
July	4.21	3.64
August	4.41	3.90
September	5.62	3.98
October	6.41	4.83
November	5.14	4.33
December	5.01	4.52
2025		
January	4.86	4.15
February	5.40	4.63
March	5.99	4.95
April (up to and including the Latest Practicable Date)	6.16	5.38

7. TAKEOVERS CODE

If a Shareholder's proportionate interest in the voting rights of the Company increases on the Company exercising its powers to repurchase securities pursuant to the Repurchase Mandate, such increase will be treated as an acquisition for the purposes of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, Mr. Chen Xueli was deemed to be interested in 2,099,755,676 Shares for the purpose of the SFO, representing approximately 45.99% of the Company's total issued Shares (excluding 4,820,000 treasury shares). In the event that the Board exercises in full the power to repurchase H Shares in accordance with the terms of the Repurchase Mandate (assuming no change in shareholdings between the Latest Practicable Date and the date of repurchase), the total deemed interest of Mr. Chen Xueli under the SFO would be increased to approximately 51.04% in total number of Shares in issue (excluding 4,820,000 treasury shares). Such increase would give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code. However, the Directors have no present intention to exercise the Repurchase Mandate to such extent so as to result in triggering takeover obligation or the public holding of Shares would be reduced below 25% of the issued share capital of the Company.

8. SHARE REPURCHASE MADE BY THE COMPANY

The Company has repurchased an aggregated of 4,820,000 H Shares on the Stock Exchange during the six months preceding the date of this circular, details of which are as follows:

Date of repurchase	Number of H Shares repurchased	Price per H Share	
		Highest	Lowest
11 February 2025	50,000	4.62	4.62
13 February 2025	600,000	4.95	4.86
14 February 2025	350,000	4.95	4.88
17 February 2025	86,000	4.85	4.85
21 February 2025	1,000,000	5.12	5.08
2 April 2025	22,000	6.00	6.00
3 April 2025	468,800	6.10	5.99
7 April 2025	600,000	5.48	5.32
8 April 2025	828,000	5.36	5.16
15 April 2025	500,000	5.62	5.60
16 April 2025	105,600	5.49	5.47
23 April 2025	69,600	5.77	5.76
24 April 2025	140,000	5.81	5.71

Save as disclosed above, no repurchase of Shares (whether on the Stock Exchange or otherwise) have been made by the Company in the six months preceding the Latest Practicable Date.

9. GENERAL

None of the Directors nor, to the best of their knowledge, having made all reasonable enquiries, any of their close associates (as defined in the Listing Rules) presently intends to sell H Shares to the Company under the Repurchase Mandate in the event that the Repurchase Mandate is approved by the Shareholders and the conditions (if any) to which the Repurchase Mandate are fulfilled.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any H Shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company in the event that the Repurchase Mandate is approved by its Shareholders and the conditions (if any) to which the Repurchase Mandate are fulfilled.

The Company may cancel, hold in treasury, sell or transfer the repurchased Shares, as deemed appropriate by the Board.

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the powers of the Company to make repurchases under the Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and the applicable laws, rules and regulations of the PRC.

Brief biographical detail of the Directors and Supervisor proposed for election at the Annual General Meeting is set out below.

Mr. Long Jing

Mr. Long Jing (“**Mr. Long**”), aged 51, is an executive Director and the chairman of the Board. Mr. Long joined the Company in July 2005 and served as the manager of sales management department and vice-general manager of sales of the Company until August 2018. He was the chief executive officer of the Company from August 2018 to March 2021. He has been an executive Director since December 2018 to date, a director of Shandong Weigao Orthopaedic Device Company Limited (“**Weigao Orthopaedic**”) (a subsidiary of the Company, stock code: 688161.SH) from March 2020 to date and the chairman of the Board from March 2021 to date. Prior to joining the Company, Mr. Long served as the sales chief of Shandong Plastic Materials Industry Company (山東省塑料工業總公司) from 1996 to 2002.

Mr. Long obtained a bachelor degree in marketing from Shandong Economic University and a master degree in business administration from Shandong University. He also obtained the Chinese professional qualification of Certified Public Accountant (CPA), with nearly 20 years of experiences in sales and operation management in the medical device industry.

Subject to the Shareholder’s approval at the Annual General Meeting, the Company will enter into a service contract with Mr. Long to renew the terms of his appointment for a term of three years commencing from the date of the Annual General Meeting. Mr. Long is subject to re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the Articles of Association. The service contract may be terminated by either party by giving to the other party not less than three month’s written notice. Mr. Long is entitled to a proposed remuneration of RMB3,000,000 per annum. As at the Latest Practicable Date, Mr. Long is interested in 480,000 H Shares and 6,000,000 Domestic Shares.

Save as disclosed above and as at the Latest Practicable Date, Mr. Long does not have any relationship with any other Directors, senior management or substantial or controlling Shareholders of the Company and does not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above and as at the Latest Practicable Date, Mr. Long does not hold any directorships in the last 3 years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above and as at the Latest Practicable Date, there is no other information about Mr. Lu that needs to be brought to the attention of the holders of securities or disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

Mr. Lu Junqiang

Mr. Lu Junqiang (“**Mr. Lu**”), aged 51, is an executive Director and a director and a general manager of Weigao Orthopaedic (stock code: 688161.SH), a subsidiary of the Company. Mr. Lu joined the Company in October 2000 and served as the regional manager, sales manager of Eastern China and deputy general manager of the medical devices products until January 2018. Mr. Lu was the deputy general manager of sales of Weigao Orthopaedic from January 2018 to September 2019; and the director of Weigao Orthopaedic in September 2018 and the general manager of Weigao Orthopaedic from September 2019 until present. Mr. Lu obtained a master’s degree of business administration from the University of Wales in the United Kingdom and has more than 20 years of experience in sales and operation management in the medical device industry.

Subject to the Shareholder’s approval at the Annual General Meeting, the Company will enter into a service contract with Mr. Lu to renew the terms of his appointment for a term of three years commencing from the date of the Annual General Meeting. Mr. Lu is subject to re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the Articles of Association. The service contract may be terminated by either party by giving to the other party not less than three month’s written notice. Mr. Lu is entitled to a proposed remuneration of RMB1,600,000 per annum. As at the Latest Practicable Date, Mr. Lu is interested in 400,000 A shares in Weigao Orthopaedic.

Save as disclosed above and as at the Latest Practicable Date, Mr. Lu does not have any relationship with any other Directors, senior management or substantial or controlling Shareholders of the Company and does not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above and as at the Latest Practicable Date, Mr. Lu does not hold any directorships in the last 3 years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above and as at the Latest Practicable Date, there is no other information about Mr. Lu that needs to be brought to the attention of the holders of securities or disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

Mr. Li Guohui

Mr. Li Guohui (“**Mr. Li**”), aged 52, has been appointed as an independent non-executive Director in June 2022 and is also the chairman of the audit committee and a member of each of the remuneration committee, nomination committee and corporate governance committee of the Company. Currently, Mr. Li is the executive director, chief strategy officer, chief financial officer and company secretary of China Aircraft Leasing Group Holdings Limited (stock code: 1848.HK) and an independent non-executive director of Space Group Holdings Limited (stock code: 2448.HK). From July 2019 to December 2022, Mr. Li worked in Zhongsheng Group Holdings Limited (“**Zhongsheng Group**”, stock code: 0881.HK). His last position was joint chief financial officer. He was also an executive director of Zhongsheng Group from June 2020 to December 2022. From August 2013 to July 2019, Mr. Li was the vice president, chief financial officer and executive director of China Resources Pharmaceutical Group Limited (stock code: 3320.HK), a non-executive director of Dong-E E-Jiao Co., Ltd. (stock code: 000423.SZ) and China Resources Double Crane Pharmaceutical Co., Ltd. (stock code: 600062.SH) and a supervisor of Sanjiu Medical & Pharmaceutical Co., Ltd. (stock code: 000999.SZ). He was the accounting director of the finance department of China Resources (Holdings) Company Limited from September 2009 to August 2013; a senior analyst of IMC Development Management Company in Hong Kong from April 2006 to September 2009; and a M&A investment analyst in IMC Fanya, Singapore from October 2005 to April 2006.

Mr. Li obtained a bachelor’s degree in naval architecture and marine engineering from Wuhan University of Technology, a master’s degree in business administration from Wuhan University, a master’s degree in financial management from Nanyang Technological University in Singapore and obtained professional qualifications as a Chartered Financial Analyst (CFA) qualified by the CFA Institute of Chartered Financial Analyst and a Certified Public Accountant (CPA) qualified by the Singapore Institute of Chartered Accountants.

Subject to the Shareholder’s approval at the Annual General Meeting, the Company will enter into a service contract with Mr. Li to renew the terms of his appointment for a term of three years commencing from the date of the Annual General Meeting. Mr. Li is subject to re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the Articles of Association. The service contract may be terminated by either party by giving to other party not less than three month’s written notice. Mr. Li is entitled to a director’s fee of HK\$230,000 per annum, which was determined with reference to his qualification, level of duties and responsibilities undertaken in the Company and the prevailing market conditions.

Save as disclosed above and as at the Latest Practicable Date, Mr. Li does not have any relationship with any other Directors, senior management or substantial or controlling Shareholders of the Company and does not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above and as at the Latest Practicable Date, Mr. Li does not hold any directorships in the last 3 years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above and as at the Latest Practicable Date, there is no other information about Mr. Li that needs to be brought to the attention of the holders of securities or disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

Mr. Song Dapeng

Mr. Song Dapeng (“**Mr. Song**”), aged 47, is a shareholder representative supervisor of the Company and is the director of the audit center of Weigao Holding. Mr. Song joined Weigao Holding in November 2009 and has served as the supervisor of the audit and risk management department, manager of the audit and risk management department and assistant to general manager of Weigao Holding. Prior to joining Weigao Holding, Mr. Song worked as the manager of the audit department of Weihai Jinzheng Accountancy* (威海金正會計師事務所) from January 2006 to October 2009. Mr. Song has been the chairman of the supervisory committee of Huadong Automation (stock code: 002248.SZ) from March 2021 to date. Mr. Song graduated from Shandong University of Finance and Economics* (山東經濟學院) majoring in accounting.

NOTICE OF ANNUAL GENERAL MEETING

WEGO威高

山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the “AGM”) of Shandong Weigao Group Medical Polymer Company Limited* (山東威高集團醫用高分子製品股份有限公司) (the “Company”) will be held at 2/F, 1 Weigao Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the PRC at 9:00 a.m. on Tuesday, 27 May 2025 to consider and, if though fit, pass the following resolutions:

ORDINARY RESOLUTIONS

1. To consider and approve the audited consolidated financial statements of the Company for the year ended 31 December 2024.
2. To consider and approve the report of the board of directors of the Company (the “Board”) for the year ended 31 December 2024.
3. To consider and approve the report of the Supervisory Committee of the Company for the year ended 31 December 2024.
4. To declare a final dividend of RMB0.1235 per share of RMB0.10 each in the Company for the year ended 31 December 2024.
5. To consider and approve the proposal for the re-appointment of Deloitte Touche Tohmatsu as the auditor of the Company for a term until the next annual general meeting of the Company and to authorise the Board to determine their remuneration.
6. To consider and approve the re-election of Mr. Long Jing as an executive director of the Company.
7. To consider and approve the re-election of Mr. Lu Junqiang as an executive director of the Company.
8. To consider and approve the re-election of Mr. Li Guohui as an independent non-executive director of the Company.

* For identification purpose only

NOTICE OF ANNUAL GENERAL MEETING

9. To consider and approve the re-election of Mr. Song Dapeng as a supervisor of the Company.
10. To consider and authorise the Board to approve the remuneration of the directors of the Company.

SPECIAL RESOLUTIONS

11. To consider and approve the grant of an unconditional general mandate (the “**General Mandate**”) to the Board to issue, allot and deal with overseas-listed shares in the share capital of the Company (“**H Shares**”) and/or non-listed domestic shares in the share capital of the Company (“**Domestic Shares**”) (including but not limited to ordinary shares, preference shares, securities convertible into shares, options, warrants or similar rights to subscribe for any shares or such convertible securities, and to resell any treasury repurchased) and to make or grant offers, agreements and options in respect thereof, subject to the following conditions:
 - (a) the General Mandate shall not extend beyond the Relevant Period (as defined in paragraph (d) below) save that the Board may during the Relevant Period make or grant offers, agreements or options which might require the exercise of such powers after the end of the Relevant Period;
 - (b) (i) The number of the H Shares to be allotted, issued and dealt with as determined by the Board or the chairman of the Board (the “**Chairman**”) and its authorized persons in accordance with the General Mandate shall not exceed 10% of the number of the H Shares in issue (excluding any treasury shares) at the time when this resolution is considered and passed. The discount (if any) of the issue price of the H Shares to be allotted, issued and dealt with as determined by the Board or the Chairman and its authorized persons in accordance with the General Mandate shall not exceed 10% of the benchmark price of the securities (rather than the 20% as prescribed under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)).

NOTICE OF ANNUAL GENERAL MEETING

- (ii) The number of the Domestic Shares to be allotted, issued and dealt with as determined by the Board or the Chairman and its authorized persons in accordance with the General Mandate shall not exceed 10% of the number of the Domestic Shares in issue at the time when this resolution is considered and passed. The discount (if any) of the issue price of the Domestic Shares to be allotted, issued and dealt with as determined by the Board or the Chairman and its authorized persons in accordance with the General Mandate shall not exceed 10% of the benchmark price of the securities (rather than the 20% as prescribed under the Listing Rules).
- (c) the Board will only exercise its power under such mandate in accordance with the PRC Company Law and the Listing Rules or other applicable laws, rules and regulations of other government regulatory bodies and only if all necessary approvals from the China Securities Regulatory Commission and/or other relevant PRC government authorities are obtained;

after the issuance of Shares, one of the Directors be and is hereby authorised:

- (i) to approve, execute and do or procure to be executed and done all such documents, deeds and things as it may consider necessary in connection with the issue of such new Shares of the Company, including, without limitation, determining the time and place of issue, making all necessary applications to the relevant authorities, and entering into underwriting agreement(s) or any other agreements;
- (ii) to determine the use of proceeds and to make necessary filings and registration with the PRC, Hong Kong and other relevant authorities; and
- (iii) to make such amendments to the articles of association of the Company as it may deem appropriate for the increase of the registered capital of the Company and to reflect the new share capital structure of the Company after the intended allotment and issue of the Shares of the Company pursuant to this resolution.

NOTICE OF ANNUAL GENERAL MEETING

- (d) for the purpose of this resolution,

“**Relevant Period**” means the period from the date of passing this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of this resolution; or
 - (ii) the expiry date of the 12-month period following the passing of this resolution; or
 - (iii) the date on which the authority granted to the Board as set out in this resolution is revoked or varied by a special resolution of the Shareholders of the Company at any general meetings.
12. To consider and approve the granting of a general mandate to the Board to repurchase H Shares, during the Relevant Period (as defined in paragraph (c) below):

“**THAT:**

- (a) by reference to market conditions and in accordance with needs of the Company, repurchase the H Shares not exceeding 10% of the number of the H Shares in issue (excluding any treasury shares) and having not been repurchased at the time when this resolution is passed at annual general meeting;
- (b) the Board be authorised to (including but not limited to the following):
 - (i) determine detailed repurchase plan, including but not limited to repurchase price, number of shares to repurchase, timing of repurchase and period of repurchase, etc.;
 - (ii) open overseas share accounts and carry out the foreign exchange approval and the foreign exchange change registration procedures in relation to transmission of repurchase fund overseas; and
 - (iii) subject to compliance with applicable laws and the Listing Rules, to determine whether to hold the repurchased shares as treasury shares or carry out cancellation procedures for repurchased shares, reduce registered capital of the Company in order to reflect the amount of shares repurchased in accordance with the authorisation received by the Board under paragraph (a) of this special resolution and make corresponding amendments to the articles of association of the Company as it thought fit and necessary in order to reflect the reduction of the registered capital of the Company and carry out any other necessary actions and deal with any necessary matters in order to repurchase relevant shares in accordance with paragraph (a) of this special resolution.

NOTICE OF ANNUAL GENERAL MEETING

(c) For the purposes of this special resolution:

“**Relevant Period**” means the period from the passing of this special resolution until the earliest of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of this resolution; or
- (ii) the expiry date of the 12-month period following the passing of this resolution; or
- (iii) the date on which the authority granted to the Board as set out in this resolution is revoked or varied by a special resolution of the Shareholders of the Company at any general meetings;

except where the Board has resolved to repurchase H Shares during the Relevant Period and such share repurchase plan may have to be continued or implemented after the Relevant Period.”

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

Weihai, the PRC
30 April 2025

As at the date of this notice, the Board comprises:

Executive Directors

Mr. Long Jing (*Chairman*)
Mr. Cong Rinan (*Chief Executive Officer*)
Mr. Lu Junqiang
Mr. Wang Daoming

Non-executive Directors

Mr. Tang Zhengpeng (*Vice Chairman*)
Mr. Chen Lin
Mrs. Yan Xia

Independent non-executive Directors

Mr. Li Guohui
Mrs. Meng Hong
Mr. Li Qiang
Mr. Sun Heng

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. For the purpose of determining who may attend the Annual General Meeting to be held on Tuesday, 27 May 2025, the register of holders of H Shares of the Company will be closed from Wednesday, 21 May 2025 to Tuesday, 27 May 2025 (both dates inclusive), during which no transfer of H Shares will be registered. In order to qualify for entitlement to attending and voting in the Annual General Meeting, all transfers of H Shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company's H Share registrar, Tricor Investor Services Limited for registration not later than 4:30 p.m. on Tuesday, 20 May 2025.

For the purpose of determining who may be entitled to receive the final dividend of the Company (subject to approval by the Shareholders at the Annual General Meeting), the register of holders of H Shares of the Company will be closed from Wednesday, 4 June 2025 to Tuesday, 10 June 2025 (both dates inclusive), during which no transfer of H Shares will be registered. In order to qualify for entitlement to the final dividend, all transfers of H Shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company's H Share Registrar, Tricor Investor Services Limited for registration not later than 4:30 p.m. on Tuesday, 3 June 2025.

The address of Tricor Investor Services Limited is as follows:

17/F
Far East Finance Centre
16 Harcourt Road
Hong Kong
Fax: (852) 2810 8185

2. In accordance with the Listing Rules, any vote of shareholders at a general meeting must be taken by poll. As such, the resolutions set out in the notice of Annual General Meeting will be voted by poll. Results of the poll voting will be published on the Company's website at www.weigaogroup.com and the website of Hong Kong Exchanges and Clearing Limited at www.hkexnews.hk after the Annual General Meeting.
3. Any shareholder entitled to attend and vote at the Annual General Meeting convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company.
4. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and deposited at the Company's H Share registrar, Tricor Investor Services Limited (for holders of H Shares), at least 24 hours before the Annual General Meeting or any adjourned meeting thereof.
5. Completion and return of a proxy form will not preclude you from attending and voting at the Annual General Meeting or any adjourned meeting thereof if you so wish.
6. In case of joint shareholdings, the vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
7. The Annual General Meeting is expected to last for about half a day. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses. Shareholders or their proxies shall produce their identity documents when attending the Annual General Meeting.